
Quarterly report 2023-Q2
added 08-08-2023
SmileDirectClub Revenue 2011-2026 | SDC
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue SmileDirectClub
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 471 M | 638 M | 657 M | 750 M | 423 M | 146 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 750 M | 146 M | 514 M |
Quarterly Revenue SmileDirectClub
| 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 102 M | - | 107 M | 126 M | 152 M | 126 M | 138 M | 174 M | 199 M | 185 M | 169 M | 107 M | 197 M | 197 M | 180 M | 196 M | 178 M | 129 M | 120 M | 107 M | 68.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 199 M | 68.4 M | 148 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aethlon Medical
AEMD
|
574 K | $ 2.11 | 8.21 % | $ 3.29 M | ||
|
AdaptHealth Corp.
AHCO
|
3.24 B | $ 10.42 | -1.65 % | $ 1.41 B | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
Alphatec Holdings
ATEC
|
764 M | $ 12.6 | 2.61 % | $ 1.89 B | ||
|
Butterfly Network
BFLY
|
82.1 M | $ 3.91 | 2.62 % | $ 828 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Cognyte Software Ltd.
CGNT
|
443 M | $ 8.38 | -0.24 % | $ 602 M | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
Boston Scientific Corporation
BSX
|
20.1 B | $ 69.79 | 0.95 % | $ 103 B | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.96 | 1.02 % | $ 148 M | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 37.41 | 0.35 % | $ 1.16 B | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
Cytosorbents Corporation
CTSO
|
35.6 M | $ 0.65 | -8.13 % | $ 35.4 M | ||
|
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
ClearPoint Neuro
CLPT
|
31.4 M | $ 11.03 | 2.22 % | $ 298 M | ||
|
Establishment Labs Holdings
ESTA
|
211 M | $ 63.48 | 0.21 % | $ 1.88 B | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
FONAR Corporation
FONR
|
97.6 M | $ 18.42 | 0.22 % | $ 121 M | ||
|
InMode Ltd.
INMD
|
358 M | $ 13.43 | -0.81 % | $ 868 M | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Abbott Laboratories
ABT
|
44.3 B | $ 109.95 | 1.8 % | $ 191 B | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 9.81 | 3.81 % | $ 351 M | ||
|
Bio-Rad Laboratories
BIO
|
2.57 B | $ 261.24 | -0.59 % | $ 7.37 B | ||
|
Helius Medical Technologies
HSDT
|
644 K | $ 2.19 | 3.79 % | $ 1.33 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.61 B | $ 9.01 | -2.49 % | $ 694 M | ||
|
AxoGen
AXGN
|
225 M | $ 32.84 | 1.55 % | $ 1.51 B | ||
|
Align Technology
ALGN
|
4 B | $ 169.45 | 3.18 % | $ 12.7 B | ||
|
Bruker Corporation
BRKR
|
3.37 B | $ 32.76 | -2.93 % | $ 4.88 K | ||
|
IRIDEX Corporation
IRIX
|
51.9 M | $ 1.33 | 2.31 % | $ 21.5 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Apyx Medical Corporation
APYX
|
52.8 M | $ 3.67 | 1.1 % | $ 151 M | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 17.11 | -1.16 % | $ 401 M | ||
|
Integer Holdings Corporation
ITGR
|
1.85 B | $ 84.12 | 1.34 % | $ 2.92 B | ||
|
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M |